NantBio offers treatments by developing molecularly targeted drugs, based on the molecular profile of the patient’s tumor.
NantBio has raised $2.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in February 2024.
NantBio is headquartered in Culver City, United States.
NantBio offers treatments by developing molecularly targeted drugs, based on the molecular profile of the patient’s tumor.
NantBio is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NantBio — Funding & Investors." VCBacked, February 9, 2024, https://www.vcbacked.co/company/nantbio. Accessed September 30, 2026.
VCBacked. (2024). NantBio — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/nantbio
{{cite web |title=NantBio — Funding & Investors |url=https://www.vcbacked.co/company/nantbio |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated